CHICAGO (August 19, 2025) – A new study is raising concerns that some widely used weight-loss drugs, including popular GLP-1 medications like Ozempic and Wegovy, may be linked to rare but serious cases of sudden vision loss.
Several lawsuits have already been filed against Novo Nordisk, the maker of both drugs, accusing the company of failing to warn patients about the risk of an eye injury known as NAION.
Salvi, Schostok & Pritchard attorney Kristen M. Stoicesu was interviewed on FOX32 about the lawsuits and what consumers should do if they experience vision loss after taking a GLP-1 medication.
In the following video, Ms. Stoicesu discusses the specifics of these new lawsuits, including the alleged failure to warn about NAION, and provides guidance for individuals who may have been impacted.
